Shares of Chindex International (Nasdaq:CHDX) have taken a tremendous swing upward. The stock is trading at $10.09 as of 10:51 a.m. ET, 20.1% above Monday's closing price of $8.40. Volume is at 51,498, 0.9 times the daily average of 56,300.
NEW YORK ( TheStreet) -- Shares of Chindex International (Nasdaq: CHDX) have taken a tremendous swing upward. The stock is trading at $10.09 as of 10:51 a.m. ET, 20.1% above Monday's closing price of $8.40. Volume is at 51,498, 0.9 times the daily average of 56,300. Chindex International has a market cap of $124.9 million and is part of the services sector and wholesale industry. Shares are down 49.1% year to date as of the close of trading on Monday. Chindex International, Inc. engages in the provision of healthcare services; and sale of medical equipment, instrumentation, and products. The company operates in two segments, Healthcare Services and Medical Products. The company has a P/E ratio of 15.7, below the average wholesale industry P/E ratio of 22.6 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Chindex International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. You can view the full Chindex International Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
Chindex (CHDX) spiked to a five-year high of $19.71 on Tuesday after the announcement that TPG and Shanghai Fosun Pharmaceutical would acquire the drug manufacturer. The deal is worth $369 million, and the consortium will pay $19.50 per share in cash for Chindex. Founder and Chief Executive Officer Roberta Lipson will stay on as CEO after the deal. The deal should give TPG and Fosun a foothold in China's private healthcare sector, which has been growing quickly as the Chinese government invests in it to alleviate pressure on public hospitals and to drive down prices through more competition in the market.